ArticleJournal of ovarian research2026
Immediate protective effect of rUCMSC-EVs on ovarian function in a cyclophosphamide -induced premature ovarian insufficiency rats: counteracting granulosa cell apoptosis.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsPremature ovarian insufficiency (POI), which is defined as the loss of ovarian activity before the age of 40 leading to amenorrhea and infertility, is often induced in female patients treated with alkylating agents such as cyclophosphamide (CTX). Currently, the standard clinical management for POI is hormone replacement therapy, which alleviates symptoms but does not restore fertility. Although multiple previous studies have demonstrated that mesenchymal stem cells and their derived extracellular vesicles can protect ovarian function and restore fertility, whether concurrent EV intervention during chemotherapy can preserve ovarian reserve remains unclear.
methodsThe rat umbilical cord mesenchymal stem cells derived extracellular vesicles (rUCMSC-EVs) in this study were isolated from the culture supernatant of rat umbilical cord mesenchymal stem cells (rUCMSC), and POI rat model was established via intraperitoneal injection of CTX and subcutaneous administration of busulfan. Concurrently with the chemotherapeutic drug injection, rUCMSC-EVs were injected into the ovaries. ELISA, histological assessment and mating experiments were used to evaluate ovarian function and reproductive outcomes. Additionally, ovarian granulosa cells were isolated and co-treated with CTX and rUCMSC-EVs to assess apoptosis and DNA repair capacity via flow cytometry and gene expression assays.
resultsTreatment with rUCMSC-EVs effectively counteracted CTX-induced ovarian damage, as evidenced by restored ovarian weight, improved follicular reserve (increased antral follicles and reduced atreic follicles), and elevated serum anti-Müllerian hormone (AMH) and estradiol (E2) levels. Consequently, EV-treated rats exhibited reduced ovarian fibrosis and apoptosis, resulting in improved pregnancy and live birth rates. Furthermore, in ovarian granulosa cells, compared to cells treated with CTX alone, co-treatment with CTX and EVs significantly reduced apoptosis and DNA damage, while upregulating the expression levels of key DNA repair molecules (including BRCA1, BRCA2, MRE11 and RAD51).
conclusionsOur study demonstrates that the combined intervention of rUCMSC-EVs and chemotherapy drugs can alleviate the apoptosis of ovarian granulosa cells, thereby preserving the ovarian function and improving the fertility of the POI rats. The reduction in granulosa cell apoptosis may be related to the enhancement of DNA damage repair capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.